Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × LY-2157299 × 1 year × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 606 Carboplatin 370 Paclitaxel 275 Cisplatin 262 Gemcitabine 247 Nivolumab 196 Pemetrexed 193 Bevacizumab 191 Docetaxel 184 Injections 163 Cyclophosphamide 148 atezolizumab 140 Capecitabine 137 Oxaliplatin 133 Fluorouracil 129 Dexamethasone 125 durvalumab 115 Fulvestrant 112 130-nm albumin-bound paclitaxel 108 Rituximab 100 fludarabine 97 Leucovorin 96 Cetuximab 95 venetoclax 87 Lenalidomide 86 Prednisone 83 enzalutamide 76 Ipilimumab 75 Azacitidine 74 Doxorubicin 73

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01582269 2025-11-24

A Study in Recurrent Glioblastoma (GB)

Eli Lilly and Company

Phase 2 Completed

158 enrolled 20 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡